Hennig, E.E.; Piątkowska, M.; Goryca, K.; Pośpiech, E.; Paziewska, A.; Karczmarski, J.; Kluska, A.; Brewczyńska, E.; Ostrowski, J.
Non-CYP2D6 Variants Selected by a GWAS Improve the Prediction of Impaired Tamoxifen Metabolism in Patients with Breast Cancer. J. Clin. Med. 2019, 8, 1087.
https://doi.org/10.3390/jcm8081087
AMA Style
Hennig EE, Piątkowska M, Goryca K, Pośpiech E, Paziewska A, Karczmarski J, Kluska A, Brewczyńska E, Ostrowski J.
Non-CYP2D6 Variants Selected by a GWAS Improve the Prediction of Impaired Tamoxifen Metabolism in Patients with Breast Cancer. Journal of Clinical Medicine. 2019; 8(8):1087.
https://doi.org/10.3390/jcm8081087
Chicago/Turabian Style
Hennig, Ewa E., Magdalena Piątkowska, Krzysztof Goryca, Ewelina Pośpiech, Agnieszka Paziewska, Jakub Karczmarski, Anna Kluska, Elżbieta Brewczyńska, and Jerzy Ostrowski.
2019. "Non-CYP2D6 Variants Selected by a GWAS Improve the Prediction of Impaired Tamoxifen Metabolism in Patients with Breast Cancer" Journal of Clinical Medicine 8, no. 8: 1087.
https://doi.org/10.3390/jcm8081087
APA Style
Hennig, E. E., Piątkowska, M., Goryca, K., Pośpiech, E., Paziewska, A., Karczmarski, J., Kluska, A., Brewczyńska, E., & Ostrowski, J.
(2019). Non-CYP2D6 Variants Selected by a GWAS Improve the Prediction of Impaired Tamoxifen Metabolism in Patients with Breast Cancer. Journal of Clinical Medicine, 8(8), 1087.
https://doi.org/10.3390/jcm8081087